JMP reiterates Cubist at strong buy

Cubist Pharmaceuticals Inc. was reiterated by JMP Securities a strong buy after positive phase 3 data on Cubicin was presented at a medical conference. JMP said it recommends buying on any "sell on the news" weakness. Shares will continue to perform as well as Cubicin sales rise, JMP said. Shares of the Lexington, Mass., pharmaceutical company were down $1.67, or 7.51%, at $20.56 on volume of 2,113,992 shares versus the three-month running average of 675,868 shares.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.